Adicet Bio CTO receives stock option grant

Adicet Bio, Inc. reported that Chief Technology Officer Don Healey received a grant of stock options covering 43,361 shares of common stock.

Accepted by SEC EDGAR 03/27/2026 - 04:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Adicet Bio, Inc. reported that Chief Technology Officer Don Healey received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the terms, 1/48th of the options vest on each of the 48 monthly anniversaries of the grant date, as long as he continues his service with the company. This is a compensation-related award rather than an open-market share purchase.

Insider Trade Summary

Grant/Award: 43,361 shares

Grant/Award 1 txn

Insider Healey Don

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	43,361	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 43,361 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 43,361 contracts (Direct)

Footnotes (1)

1. F1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adicet Bio (ACET) report in this Form 4?

Adicet Bio reported a stock option grant to its Chief Technology Officer, Don Healey. He received options for 43,361 shares as a compensation award, not an open-market purchase, with specific vesting, exercise price, and expiration terms described in the filing.

How many stock options did Adicet Bio’s CTO receive and at what exercise price?

The Chief Technology Officer received options on 43,361 shares of Adicet Bio common stock. These options carry an exercise price of $6.81 per share, meaning he can buy shares at that price once the respective tranches vest and are exercisable.

What is the vesting schedule for Don Healey’s Adicet Bio stock options?

The options vest in equal monthly installments over four years. Specifically, 1/48th of the 43,361 options vest on each monthly anniversary of the grant date, provided Don Healey maintains a service relationship with Adicet Bio on each applicable vesting date.

When do the newly granted Adicet Bio stock options expire?

The granted stock options expire on March 24, 2036. After this expiration date, any unexercised options become worthless, so they must be exercised before then, subject to vesting and any other conditions in the company’s equity plan or award agreement.

Is the Adicet Bio Form 4 transaction a market purchase or a compensation grant?

The transaction is a compensation grant, not a market purchase. The Form 4 describes a stock option award with a transaction code A, indicating a grant or award acquisition, given at no cost upfront but exercisable later at a fixed price per share.

How many Adicet Bio derivative securities does the CTO hold after this grant?

Following this transaction, Don Healey holds 43,361 derivative securities in the form of stock options. This figure reflects the total options covered by the new grant as reported, with no additional remaining derivative positions listed in the filing’s derivative summary section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Healey Don

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.81	03/25/2026		A		43,361		(1)	03/24/2036	Common Stock	43,361	$0.00	43,361	D

Explanation of Responses:

1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)